Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics, Inc. reported an equity compensation award to its Chief Scientific Officer, Joseph P. Lyssikatos. On February 12, 2026, he was granted a stock option for 112,500 shares of common stock at an exercise price of $0.00 per share. According to the filing, one quarter of this option vests on February 12, 2027, with the remainder vesting in equal monthly installments over the following three years, so long as he continues as a service provider.
He also received 18,750 restricted stock units (RSUs), each representing one share of common stock. One quarter of these RSUs vest on March 1, 2027, with additional portions vesting on each June 1, September 1, December 1, and March 1 thereafter, subject to continued service. The filing also notes indirect ownership of 740,188 shares of common stock held through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.
Enliven Therapeutics reported new equity awards for its Chief Financial Officer, Benjamin Hohl. He received stock options for 150,000 shares at an exercise price of $0.00 per share and 25,000 restricted stock units, each representing one share of common stock.
The option award vests over four years, with one-quarter vesting on February 12, 2027 and the remainder monthly thereafter, as long as he continues as a service provider. The RSUs vest on a similar multi-year schedule beginning March 1, 2027, with one-quarter vesting initially and the rest in equal quarterly installments.
Collins Helen Louise reported acquisition or exercise transactions in a Form 4 filing for ELVN. The filing lists transactions totaling 175,000 shares. Following the reported transactions, holdings were 150,000 shares.
An Enliven Therapeutics insider, Samuel Kintz, filed notice to sell 75,000 shares of the company’s common stock through Jefferies LLC, with an indicated aggregate market value of $2,004,000.00. The notice lists 59,000,000 common shares outstanding and targets an approximate sale date of 02/17/2026 on Nasdaq.
The 75,000 shares are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. The filing also reports recent sales over the past three months, including 43,743 shares sold on 01/09/2026 for gross proceeds of $1,089,200.70 and 20,000 shares on 01/20/2026 for $535,090.80.
Enliven Therapeutics insider Richard Heyman filed a notice of proposed sale under Rule 144 covering up to 1,230 shares of common stock. The planned sale through Jefferies LLC on the Nasdaq has an aggregate market value of $32,865.60, with 59,000,000 shares outstanding. The approximate sale date indicated is February 17, 2026. In the past three months, Heyman has sold Enliven securities in three transactions totaling 8,015 shares for $200,655.12, 4,285 shares for $107,125.60, and 1,230 shares for $32,901.55.
Enliven Therapeutics filed a notice of proposed insider sales under Rule 144. The filing covers up to 45,000 shares of common stock, with an aggregate market value of $1,202,400.00, to be sold through Jefferies LLC on or about February 17, 2026 on the NASDAQ exchange.
The 45,000 shares were acquired on August 9, 2022 via stock options from Enliven Therapeutics Inc. The filing also notes that 59,000,000 shares of common stock were outstanding. The seller represents they are not aware of undisclosed material adverse information about the company.
Vestal Point Capital has reported a significant passive ownership stake in Enliven Therapeutics, Inc. Through a fund and a managed account, Vestal Point and its CIO Ryan Wilder beneficially own 3,830,000 shares of Enliven common stock, representing 6.5% of the company’s outstanding shares.
The filing shows Vestal Point and Wilder share voting and dispositive power over these shares, while the Vestal Point fund and account are entitled to dividends and sale proceeds. The ownership percentage is based on 59,347,317 Enliven shares outstanding as of October 31, 2025. The stake is certified as being held in the ordinary course of business without the purpose of influencing control.
Enliven Therapeutics’ chief scientific officer, Joseph P. Lyssikatos, reported an indirect sale of company stock through a family trust. On February 6, 2026, The Lyssikatos Revocable Trust sold 5,000 shares of Enliven common stock at a weighted average price of $29.0438 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
After this transaction, the trust, for which Lyssikatos serves as trustee, beneficially owned 740,188 shares of Enliven Therapeutics common stock, reported as indirectly owned.
ELVN insider Andrew Phillips filed a notice to sell 21,844 shares of common stock through Morgan Stanley Smith Barney on or about February 2, 2026, on NASDAQ, with an aggregate market value of $611,719.38.
The shares were acquired the same day via a stock option exercise paid in cash. Phillips also sold 1,520 common shares for $42,564.10 on January 22, 2026. Common shares outstanding were 59,347,317 at the time referenced.
The Lyssikatos Revocable Trust 12/15/2011, for which Enliven Therapeutics’ Chief Scientific Officer Joseph P. Lyssikatos serves as trustee, reported pre‑planned sales of company common stock. On January 20, 2026, the trust sold 5,491 shares at a weighted average price of $26.373 per share and a further 14,509 shares at a weighted average price of $26.8995 per share, each under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following these transactions, the trust held 745,188 shares of Enliven Therapeutics common stock indirectly attributable to the reporting person.